keyword
MENU ▼
Read by QxMD icon Read
search

viral hepatitis prevention, treatment

keyword
https://www.readbyqxmd.com/read/28732085/point-of-care-screening-for-hepatitis-b-virus-infection-in-pregnant-women-at-an-antenatal-clinic-a-south-african-experience
#1
Nafiisah Chotun, Wolfgang Preiser, Christoffel Johannes van Rensburg, Pedro Fernandez, Gerhard Barnard Theron, Dieter Glebe, Monique Ingrid Andersson
BACKGROUND & AIMS: Elimination of HIV and syphilis mother-to-child transmission (MTCT) has received much attention but little consideration has been given to the possibility of elimination of HBV MTCT. In sub-Saharan Africa, HBV vertical transmission continues to be reported and it remains an important public health problem. This study aimed to assess the feasibility of screening pregnant women for HBV using a point-of-care (POC) test and implementing interventions to prevent HBV MTCT...
2017: PloS One
https://www.readbyqxmd.com/read/28706414/risk-of-hepatitis-b-reactivation-in-patients-treated-with-direct-acting-antivirals-for-hepatitis-c
#2
EDITORIAL
Ioanna Aggeletopoulou, Christos Konstantakis, Spilios Manolakopoulos, Christos Triantos
The recent introduction of direct-acting antiviral drugs (DAAs) for treatment of the hepatitis C virus (HCV) has greatly improved the management of HCV for infected patients. These viral protein inhibitors act rapidly, allowing HCV clearance and increasing the sustained virological response rates. However, hepatitis B virus (HBV) reactivation has been reported in HCV/HBV co-infected patients. Hepatitis B reactivation refers to an abrupt increase in the HBV and is well-documented in patients with previously undetected HBV DNA due to inactive or resolved HBV infection...
June 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28689856/restrictions-on-access-to-direct-acting-antivirals-for-people-who-inject-drugs-the-european-hep-core-study-and-the-role-of-patient-groups-in-monitoring-national-hcv-responses
#3
J V Lazarus, K Safreed-Harmon, S R Stumo, M Jauffret-Roustide, M Maticic, T Reic, E Schatz, J Tallada, M Harris
In 2016, the World Health Organization (WHO) called for the elimination of viral hepatitis as a public health threat and established the targets of achieving an 80% reduction in new infections and a 65% reduction in deaths from the hepatitis C virus (HCV) by 2030. If European countries are to come close to reaching the WHO targets, they must squarely address the HCV prevention, testing and treatment needs of people who inject drugs (PWID). This viewpoint reports on findings from the 2016 European Hep-CORE study, which was unique in its utilisation of patient groups as a source of hepatitis policy information...
July 6, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28675991/small-molecule-inhibitors-of-hepatitis-b-virus-nucleocapsid-assembly-a-new-approach-to-treat-chronic-hbv-infection
#4
Li Yang, Mengji Lu
Hepatitis B virus (HBV) infection is still a major health problem worldwide. The current available antiviral drugs for the treatment of chronic HBV infection do not achieve satisfactory results. Thus, it is desirable to develop novel anti-HBV drugs based the recent advances of basic research on molecular biology of HBV. HBV nucleocapsid assembly is now considered as a potential target of anti-HBV therapy. Structural and functional analysis provided essential insight of molecular interaction of the components of HBV nucleocapsid...
July 4, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28675280/-is-there-hope-for-hepatitis-delta
#5
Stefano Guglielmi, Jean-Louis Frossard, Francesco Negro
Hepatitis D or delta is a chronic liver disease globally reaching 15‑20M people. Its agent, hepatitis D virus (HDV) requires the presence of hepatitis B virus (HBV) to complete its life cycle. It represents one of the most severe forms of viral hepatitis. Current therapy with pegylated interferon alpha leads to viral eradication only in 25 % of cases. New treatments targeting the virus life cycle are sought. For example Myrcludex-B, which inhibits the entry into hepatocytes, lonafarnib which prevents the assemblage of the viral particle and the molecule REP 2139 which, among other unclear mechanisms, impedes the exit of the virus...
August 31, 2016: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28673855/immiscible-phase-filter-extraction-and-equivalent-amplification-of-genotypes-1-6-of-hepatitis-c-rna-the-building-blocks-for-point-of-care-diagnosis
#6
Mário F Neto, Matthew A Butzler, Jennifer L Reed, Xiang Rui, Mark J Fisher, David M Kelso, Sally M McFall
The lack of hepatitis C virus (HCV) diagnostic tests designed for use in decentralized settings is a major obstacle for providing access to treatment and prevention services particularly in low and middle income countries. Here we describe the development and validation of two building blocks of the HCV Quant Assay, a test in development for point-of-care use: 1) an RT-qPCR assay with noncompetitive internal control that equivalently detects the 6 major HCV genotypes and 2) an automated sample prep method using immiscible phase filter technology...
June 30, 2017: Journal of Virological Methods
https://www.readbyqxmd.com/read/28642806/the-efficacy-of-epigallocatechin-3-gallate-green-tea-in-the-treatment-of-alzheimer-s-disease-an-overview-of-pre-clinical-studies-and-translational-perspectives-in-clinical-practice
#7
REVIEW
Marco Cascella, Sabrina Bimonte, Maria Rosaria Muzio, Vincenzo Schiavone, Arturo Cuomo
Alzheimer's disease (AD) is a neurodegenerative disorder and the most common form of dementia characterized by cognitive and memory impairment. One of the mechanism involved in the pathogenesis of AD, is the oxidative stress being involved in AD's development and progression. In addition, several studies proved that chronic viral infections, mainly induced by Human herpesvirus 1 (HHV-1), Cytomegalovirus (CMV), Human herpesvirus 2 (HHV-2), and Hepatitis C virus (HCV) could be responsible for AD's neuropathology...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/28641714/hepatitis-c-treatment-in-patients-with-porphyria-cutanea-tarda
#8
Ashwani K Singal, Krishna V R Venkata, Sarat Jampana, Fakhar-Ul Islam, Karl E Anderson
BACKGROUND: Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Experience on HCV treatment in patients with PCT is limited. Recently, HCV treatment has improved with direct-acting antivirals (DAA). We review our experience on HCV treatment in patients with PCT with older and newer regimens. MATERIALS AND METHODS: A retrospective chart review was conducted. HCV treatment was attempted 22 times in 13 patients with PCT (5 attempts in 1, 2 in 5 and 1 in the other 7 patients)...
June 2017: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/28636622/inhibition-of-hepatitis-b-viral-entry-by-nucleic-acid-polymers-in-heparg-cells-and-primary-human-hepatocytes
#9
Clément Guillot, Nora Martel, Françoise Berby, Isabelle Bordes, Olivier Hantz, Matthieu Blanchet, Camille Sureau, Andrew Vaillant, Isabelle Chemin
Hepatitis B virus (HBV) infection remains a major public health concern worldwide with 240 million individuals chronically infected and at risk of developing cirrhosis and hepatocellular carcinoma. Current treatments rarely cure chronic hepatitis B infection, highlighting the need for new anti-HBV drugs. Nucleic acid polymers (NAPs) are phosphorothioated oligonucleotides that have demonstrated a great potential to inhibit infection with several viruses. In chronically infected human patients, NAPs administration lead to a decline of blood HBsAg and HBV DNA and to HBsAg seroconversion, the expected signs of functional cure...
2017: PloS One
https://www.readbyqxmd.com/read/28598793/croi-2017-highlights-of-advances-in-viral-hepatitis-and-liver-fibrosis
#10
Anne F Luetkemeyer, David L Wyles
At the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Washington, hepatitis C virus (HCV) infection was a major focus in the context of HIV-associated liver disease. Well-tolerated direct-acting antiviral (DAA) regimens have enabled effective treatment of the populations that are hardest to cure, including those with decompensated cirrhosis, and many studies examined the impact of HCV cure on hepatitis and extrahepatic outcomes. Scaling up access to DAA, and the impact that their universal availability can have on reducing prevalence were key topics...
May 2017: Topics in Antiviral Medicine
https://www.readbyqxmd.com/read/28582320/hepatitis-e-viral-infection-in-solid-organ-transplant-patients
#11
Stanley Y Fang, Hyosun Han
PURPOSE OF REVIEW: The purpose of this chapter is to review the literature published in the past 10 years with focus to the best literatures published since 2015 regarding chronic hepatitis E virus (HEV) infection in patients who received solid organ transplantation. RECENT FINDINGS: Diagnosis of this disease relies primarily on identification of HEV RNA in serum and more recently in stool as way of predicting relapse and guide therapy duration. Current management focuses primarily on primary prevention and supportive care, because additional research is needed to identify efficacious pharmacologic therapy, though use of ribavirin has shown promise in case series in treatment of some genotypes...
August 2017: Current Opinion in Organ Transplantation
https://www.readbyqxmd.com/read/28567168/nurses-knowledge-toward-hepatitis-b-and-hepatitis-c-in-guilan-iran
#12
Farahnaz Joukar, Fariborz Mansour-Ghanaei, Mohammad Reza Naghipour, Tolou Hasandokht
BACKGROUND: Health care workers (HCWs) represent high risk population for viral hepatitis infection. OBJECTIVES: This study sought to assess the knowledge of HCWs regarding hepatitis B (HBV) and hepatitis C (HCV) infection. METHODS: In a multi-center cross sectional study, all HCWs from eight teaching hospitals were invited to participate in the study and to fill in a self-administered questionnaire. RESULTS: A total of 1008 eligible HCWs have responded to the study...
2017: Open Nursing Journal
https://www.readbyqxmd.com/read/28539842/a-review-of-antiviral-use-for-the-treatment-of-chronic-hepatitis-b-virus-infection-in-pregnant-women
#13
Ariel Jaffe, Robert S Brown
Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) remains high even with the proper use of active-passive immunoprophylaxis in newborns. Mothers with significant viremia are at a much higher risk of MTCT; therefore, treatments aimed at lowering HBV DNA levels during pregnancy may ultimately decrease global disease burden. The exact threshold for treatment remains controversial; however, most studies have accepted levels greater than 2 × 5 log10 IU/mL as significant viremia. We reviewed the most recent literature on antiviral efficacy, maternal and fetal safety, and viral resistance patterns when used for short-duration therapy in pregnancy...
March 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28534962/galectin%C3%A2-9-ameliorates-fulminant-liver-injury
#14
Tomoko Tadokoro, Asahiro Morishita, Teppei Sakamoto, Shintaro Fujihara, Koji Fujita, Shima Mimura, Kyoko Oura, Takako Nomura, Joji Tani, Hirohito Yoneyama, Hisakazu Iwama, Takashi Himoto, Toshiro Niki, Mitsuomi Hirashima, Tsutomu Masaki
Fulminant hepatitis is a severe liver disease resulting in hepatocyte necrosis. Galectin‑9 (Gal‑9) is a tandem‑repeat‑type galectin that has been evaluated as a potential therapeutic agent for various diseases that regulate the host immune system. Concanavalin A (ConA) injection into mice results in serious, immune‑mediated liver injury similar to human viral, autoimmune and fulminant hepatitis. The present study investigated the effects of Gal‑9 treatment on fulminant hepatitis in vivo and the effect on the expression of microRNAs (miRNAs), in order to identify specific miRNAs associated with the immune effects of Gal‑9...
July 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28478826/novel-aspects-of-defensins-involvement-in-virus-induced-autoimmunity-in-the-central-nervous-system
#15
Evangelos I Kazakos, Jannis Kountouras, Stergios A Polyzos, Georgia Deretzi
Recent research on re-circulation of interstitial fluid from the brain parenchyma to the periphery and its inferred importance in immune surveillance dysregulation are changing our conceptualization of the pathophysiology of virus-induced autoimmunity. In this context, it is necessary to reassess the immunomodulatory properties of human defensins that are variably expressed by cerebral microglia, astrocytes and choroid plexus epithelial cells and exhibit complex and often confounding roles in neuroinflammatory processes...
May 2017: Medical Hypotheses
https://www.readbyqxmd.com/read/28464899/prevalence-of-hepatitis-b-and-c-infection-in-persons-living-with-hiv-enrolled-in-care-in-rwanda
#16
Justine Umutesi, Bryony Simmons, Jean D Makuza, Donatha Dushimiyimana, Aimable Mbituyumuremyi, Jean Marie Uwimana, Nathan Ford, Edward J Mills, Sabin Nsanzimana
BACKGROUND: Hepatitis B (HBV) and C (HCV) are important causes of morbidity and mortality in people living with human immunodeficiency virus (HIV). The burden of these co-infections in sub-Saharan Africa is still unclear. We estimated the prevalence of the hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCVAb) among HIV-infected individuals in Rwanda and identified factors associated with infection. METHODS: Between January 2016 and June 2016, we performed systematic screening for HBsAg and HCVAb among HIV-positive individuals enrolled at public and private HIV facilities across Rwanda...
May 2, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28464883/late-presentation-of-chronic-viral-hepatitis-for-medical-care-a-consensus-definition
#17
Stefan Mauss, Stanislas Pol, Maria Buti, Erika Duffell, Charles Gore, Jeffrey V Lazarus, Hilje Logtenberg-van der Grient, Jens Lundgren, Antons Mozalevskis, Dorthe Raben, Eberhard Schatz, Stefan Wiktor, Jürgen K Rockstroh
INTRODUCTION: We present two consensus definitions of advanced and late stage liver disease being used as epidemiological tools. These definitions can be applied to assess the morbidity caused by liver diseases in different health care systems. We focus is on hepatitis B and C virus infections, because effective and well tolerated treatments for both of these infections have greatly improved our ability to successfully treat and prevent advanced and late stage disease, especially if diagnosed early...
May 3, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28458139/chlorogenic-acid-inhibits-hepatocellular-carcinoma-in-vitro-and-in-vivo
#18
Yuan Yan, Na Liu, Ni Hou, Lei Dong, Jie Li
Curative treatment of patients with hepatocellular carcinoma (HCC) is poor. There is an urgent need to develop more effective strategies for the chemoprevention of HCC. Chlorogenic acid (CGA), a type of polyphenol present in the diet, especially from coffee, has many biological activities. Patients with viral hepatitis who drank coffee everyday experienced a reduction in the incidence of HCC. In the present study, we evaluated the effects of CGA on HCC. CGA inhibited the proliferation of HepG2 cells in vitro and the progression of HepG2 xenograft in vivo...
April 18, 2017: Journal of Nutritional Biochemistry
https://www.readbyqxmd.com/read/28449246/review-article-hepatitis-e-a-concise-review-of-virology-epidemiology-clinical-presentation-and-therapy
#19
REVIEW
M C Donnelly, L Scobie, C L Crossan, H Dalton, P C Hayes, K J Simpson
BACKGROUND: Hepatitis E virus (HEV) is a leading cause of acute icteric hepatitis and acute liver failure in the developing world. During the last decade, there has been increasing recognition of autochthonous (locally acquired) HEV infection in developed countries. Chronic HEV infection is now recognised, and in transplant recipients this may lead to cirrhosis and organ failure. AIM: To detail current understanding of the molecular biology of HEV, diagnostic and therapeutic strategies and propose future directions for basic science and clinical research...
April 27, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28447325/interferon-free-therapy-with-sofosbuvir-plus-ribavirin-for-successful-treatment-of-genotype-2-hepatitis-c-virus-with-lichen-planus-a-case-report
#20
Ayumu Yoshikawa, Katsumi Terashita, Kenichi Morikawa, Soichiro Matsuda, Takahiro Yamamura, Koichiro Sarashina, Shintaro Nakano, Yoshimitsu Kobayashi, Susumu Sogabe, Kazuhiro Takahashi, Shin Haba, Hisashi Oda, Tatsuro Takahashi, Takuto Miyagishima, Naoya Sakamoto
Hepatitis C virus (HCV) infection remains the main cause of liver disease and can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV may also develop extrahepatic manifestations in the skin, eyes, joints, kidneys, nervous system, and immune system. In fact, several studies reported that up to 70% of HCV patients experienced extrahepatic manifestations. Lichen planus (LP), which is an immune system disorder that is triggered by viral infections, allergens, and stress, can affect the skin, mouth, nails, and scalp...
June 2017: Clinical Journal of Gastroenterology
keyword
keyword
81791
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"